Researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS), working with colleagues at Johns Hopkins and Florida State University have identified compounds that “potentially can be used to inhibit Zika virus replication and reduce its ability to kill brain cells.”
Although Louisiana has yet to see any locally-acquired Zika infections, another mosquito-borne virus, West Nile, remains endemic in the state.
A recent analysis published by the Centers for Disease Control and Prevention has produced results that strengthen the link between Zika virus infection and Guillain-Barré syndrome.
A recent report from the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report states that congenital Zika infection may be associated with hearing loss.
New information about how helminths regulate their hosts’ immune system may provide valuable insight for therapies to fight inflammatory diseases.
On Friday, August 26, 2016, the FDA amended its blood collection guidance, stating that all blood donations in US states and territories be tested for Zika virus infection, to ensure the safety of the nation’s blood supply.
On Monday, the US Food and Drug Administration skirted normal approval channels and issued Emergency Authorization for a Zika diagnostic test from the Swiss drug maker Roche.
News has emerged of a case in Maryland involving the identification of Zika infection in a woman who had sexual contact with a man who did not know he was sick because he was asymptomatic.
A multidisciplinary team at Yale University School of Medicine have created a mouse model for vaginal Zika virus infection.
With 43 “local” cases of Zika virus infection now reported in Florida, and as far north as St. Petersburg, health officials in other Gulf states are ramping up responses in the event of potential outbreaks—even as there remains some disagreement as to the true nature of the threat of local transmission in the United States.
Public health experts are predicting that there will likely be localized cases of the virus in flood-ravaged Louisiana as well as in Texas before the end of the summer.
Researchers analyzed soluble forms of the B cell antigens CD27 and CD38 (sCD27 and sCD38, respectively) in the plasma of children with dengue and have suggested a role for these soluble forms as biomarkers of progression of the disease.
Reports of active transmission in a second area of Florida have been confirmed.
In the first research of its kind, an interdisciplinary group of scientists analyzed three Zika strains in second trimester fetal neural stem cells (fNSC) to identify which viral proteins cause congenital microcephaly. Since Zika causes significant neurological impairment, early diagnosis is imperative.
The El Paso resident is said to have contracted the infection while visiting Miami, Florida, where active Zika transmission has been confirmed
The US Department of Health and Human Services has declared a public health emergency in Puerto Rico, in response to tens of thousands of Zika diagnoses.
As the number of locally-acquired Zika cases rises in Florida, mathematicians are researching a new approach to control vector populations.
According to an update on the environmental review, the FDA considered thousands of comments from the public prior to publishing its final environmental assessment.
WRAIR announced that their Zika purified inactivated virus vaccine succesfully prevented infection in nonhuman primates.
The approach used in the development of this vaccine was previously implemented by NIAID in a West Nile virus vaccine, which was found to be safe and effective in Phase I trials.
The rapid spread of Zika throughout Puerto Rico coupled with the introduction of active transmission in Florida has prompted the Centers for Disease Control and Prevention (CDC) to award millions in Zika funding to US states and territories.
The US Food and Drug Administration approved the VERSANT Zika RNA 1.0 Assay (kPCR) Kit for Emergency Use Authorization, as the number of locally transmitted Zika cases rose to 14.
The four previously reported non–travel-related cases of Zika infection have now been confirmed to be locally acquired in Miami-Dade county, Florida.
An international team of researchers has identified a potential role for certain monoclonal antibodies in developing a treatment for Zika virus.
In response to the growing outbreak, and the escalating need for a vaccine that can be used in infants, those who are immunocompromised, and other populations in whom currently available vaccines are not to be administered, the NIAID has entered a vaccine manufactured by Bavarian Nordic into Phase I trials.
